India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc, announced the launch of CE marked fourth-generation flow diverter, PipelineTM Vantage with Shield Technology.TM
This device allows physicians to deliver, deploy and treat brain aneurysms, and intracranial aneurysms, with greater ease and reliability while providing a scaffold that promotes growth of cells in the inner lining of the target blood vessel.
Cerebral or brain aneurysm is a condition where there is a ballooning or weakening of the inside wall of an artery in the brain. As a result of the weakening, the artery bulges out and can burst or rupture due to the pressure of the blood flow. The rupture can cause profuse internal bleeding, stroke, and even death.
Aneurysm flow diversion is a minimally invasive treatment in which a device known as a neurovascular stent is placed in the parent blood vessel of a brain aneurysm which may divert blood flow away from the aneurysm. Advances in flow diversion over the last 10 years have helped to significantly reduce the rate of aneurysm rupture.
Over time, blood flow into the aneurysm may slow down, eventually ceasing to enter the aneurysm altogether. As the body’s natural healing process works with the flow diversion device, the blood vessel may heal, and the aneurysm may shrink.
Every year in India, around 76,000 to 200,000 cases of aneurysmal subarachnoid hemorrhage are reported. Brain aneurysms are most prevalent between 35 and 60 years of age and about 40% of the ruptures are fatal.
Medtronic has introduced a warranty program called the PED Warranty Program. Through this program, patients treated with Medtronic’s Pipeline Embolization Device (Pipeline™ Flex Embolization Device with Shield Technology™/ Pipeline™ Vantage with Shield Technology™) will receive a warranty coverage.
Last updated: December 26th, 2025
